Anders Lundstrom

Anders brings over 30 years of global pharmaceutical/biotech experience. He is currently Executive Vice President and Chief Commercial Officer at Banner Life Sciences where he is planning and executing a US launch of a novel treatment of Multiple Sclerosis. He has previously held senior commercial and general management roles in AstraZeneca, Biogen, Orexo AB, where he was President and CEO, EMD Serono, and Santhera Pharmaceuticals. Anders holds a MSc in Pharmacy from Uppsala University and a Diploma in Business Administration from IHM, Stockholm. He will join the Remuneration Committee, replacing Rolf Hoffmann who, as previously announced, is not seeking re-election at the next Annual General Meeting.